Related Experiment Videos
Blocking cytokines with genes
C H Evans1, S C Ghivizzani, P D Robbins
1Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pennsylvania, USA. cevans@vms.cis.pitt.edu
Abstract:
The pathophysiology of rheumatoid arthritis (RA) is primarily driven by proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor alpha. Several biological agents have been identified that effectively block the activity of these cellular messengers, and administration of these agents to animal models of RA and human patients has been found to have therapeutic benefit. The application of gene therapy for the treatment of RA and other articular diseases is being explored to overcome current limitations with delivery of therapeutics to joint tissues. To date, laboratory research has focused on two main areas: (1) evaluation of gene delivery approaches and (2) identification of therapeutic gene products. Considerable progress has been reported with the use of local gene delivery to synovial cells by both in vivo and ex vivo methods and by systemic administration of gene delivery vectors via the circulation. Gene products that have therapeutic efficacy in animal models of RA include: IL-1 receptor antagonist, soluble IL-1 receptor I, soluble tumor necrosis factor receptor II, viral IL-10, and transforming growth factor beta, among others. The success of these laboratory studies has led to the implementation of a Phase I clinical trial to asses the safety and feasibility of using gene therapy in the treatment of RA.
Insights
Gene therapy shows promise for treating rheumatoid arthritis (RA) by targeting key inflammatory cytokines. Early studies and a Phase I clinical trial are evaluating its safety and effectiveness for joint diseases.
Area of Science:
- Rheumatology
- Molecular Biology
- Gene Therapy
Background:
- Rheumatoid arthritis (RA) pathophysiology involves proinflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor alpha.
- Biological agents blocking these cytokines offer therapeutic benefits in RA models and patients.
- Limitations in delivering therapeutics to joint tissues necessitate novel treatment strategies like gene therapy.
Purpose of the Study:
- To explore gene therapy as a treatment for rheumatoid arthritis (RA) and other articular diseases.
- To evaluate gene delivery approaches and identify effective therapeutic gene products for RA.
- To assess the safety and feasibility of gene therapy for RA through a Phase I clinical trial.
Main Methods:
- Investigating local gene delivery to synovial cells (in vivo and ex vivo) and systemic administration of gene vectors.
- Identifying and testing therapeutic gene products, including IL-1 receptor antagonist, soluble IL-1 receptor I, soluble tumor necrosis factor receptor II, viral IL-10, and transforming growth factor beta.
- Conducting a Phase I clinical trial to evaluate safety and feasibility.
Main Results:
- Significant progress in evaluating gene delivery methods for RA treatment.
- Demonstrated therapeutic efficacy of various gene products in animal models of RA.
- Successful initiation of a Phase I clinical trial based on promising laboratory findings.
Conclusions:
- Gene therapy presents a viable approach to overcome challenges in RA treatment delivery.
- Further research and clinical trials are warranted to establish gene therapy's role in managing RA.
- The development of targeted gene therapies holds potential for improved outcomes in articular diseases.